Biomerica Inc Stock Price, News & Analysis

Welcome to our dedicated page for Biomerica news (Ticker: BMRA), a resource for investors and traders seeking the latest updates and insights on Biomerica stock.

Biomerica, Inc. (NASDAQ: BMRA) is a global biomedical technology company focused on advanced diagnostic and therapeutic products, with an emphasis on gastrointestinal and inflammatory diseases. The Biomerica news feed on Stock Titan highlights company announcements that explain how its diagnostic-guided therapies, rapid screening tests, and contract development and manufacturing (CDMO) services are evolving over time.

Readers can follow updates on the inFoods® IBS diagnostic-guided therapy, including clinical evidence, commercialization partnerships, and reimbursement milestones. Recent news has covered the American Medical Associations approval of a PLA code for inFoods IBS and the Centers for Medicare & Medicaid Services (CMS) decision to set a national Medicare payment rate for the test. Articles also describe the launch of the AI-backed inFoods IBS Trigger Food Navigator, a digital companion tool designed to support personalized IBS dietary therapy.

Biomerica news also covers regulatory authorizations and international expansion for its rapid screening portfolio. Examples include authorization by the Egyptian Drug Authority for the companys complete screening test portfolio and approvals by the United Arab Emirates Ministry of Health and Prevention for the Fortel® Ulcer and Fortel® Kidney tests for home use. These items provide insight into how Biomericas products are being introduced into new markets and care settings.

Investors and healthcare observers can also track updates on Biomericas expanding CDMO services, board and governance changes, and periodic financial results that discuss revenue mix, cost discipline, and the shift toward higher-margin diagnostic-guided therapy products and services. Bookmark this page to monitor BMRA news related to product launches, clinical publications, regulatory developments, commercial partnerships, and strategic initiatives as disclosed by the company.